Machine learning approaches to drug response prediction: challenges and recent progress
- PMID: 32566759
- PMCID: PMC7296033
- DOI: 10.1038/s41698-020-0122-1
Machine learning approaches to drug response prediction: challenges and recent progress
Abstract
Cancer is a leading cause of death worldwide. Identifying the best treatment using computational models to personalize drug response prediction holds great promise to improve patient's chances of successful recovery. Unfortunately, the computational task of predicting drug response is very challenging, partially due to the limitations of the available data and partially due to algorithmic shortcomings. The recent advances in deep learning may open a new chapter in the search for computational drug response prediction models and ultimately result in more accurate tools for therapy response. This review provides an overview of the computational challenges and advances in drug response prediction, and focuses on comparing the machine learning techniques to be of utmost practical use for clinicians and machine learning non-experts. The incorporation of new data modalities such as single-cell profiling, along with techniques that rapidly find effective drug combinations will likely be instrumental in improving cancer care.
Keywords: Combination drug therapy; High-throughput screening; Pharmacogenetics.
© The Author(s) 2020.
Conflict of interest statement
Competing interestsThe authors declare no competing interests.
Figures
Similar articles
-
Machine learning methods, databases and tools for drug combination prediction.Brief Bioinform. 2022 Jan 17;23(1):bbab355. doi: 10.1093/bib/bbab355. Brief Bioinform. 2022. PMID: 34477201 Free PMC article.
-
Clinical intelligence: New machine learning techniques for predicting clinical drug response.Comput Biol Med. 2019 Apr;107:302-322. doi: 10.1016/j.compbiomed.2018.12.017. Epub 2019 Jan 3. Comput Biol Med. 2019. PMID: 30771879
-
Deep learning methods for drug response prediction in cancer: Predominant and emerging trends.Front Med (Lausanne). 2023 Feb 15;10:1086097. doi: 10.3389/fmed.2023.1086097. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36873878 Free PMC article. Review.
-
A novel machine learning-based approach for the computational functional assessment of pharmacogenomic variants.Hum Genomics. 2021 Aug 9;15(1):51. doi: 10.1186/s40246-021-00352-1. Hum Genomics. 2021. PMID: 34372920 Free PMC article.
-
Machine learning in the prediction of cancer therapy.Comput Struct Biotechnol J. 2021 Jul 8;19:4003-4017. doi: 10.1016/j.csbj.2021.07.003. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 34377366 Free PMC article. Review.
Cited by
-
Integrated drug response prediction models pinpoint repurposed drugs with effectiveness against rhabdomyosarcoma.PLoS One. 2024 Jan 26;19(1):e0295629. doi: 10.1371/journal.pone.0295629. eCollection 2024. PLoS One. 2024. PMID: 38277404 Free PMC article.
-
Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images.Front Med (Lausanne). 2023 Mar 7;10:1058919. doi: 10.3389/fmed.2023.1058919. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36960342 Free PMC article.
-
Can Systems Biology Advance Clinical Precision Oncology?Cancers (Basel). 2021 Dec 16;13(24):6312. doi: 10.3390/cancers13246312. Cancers (Basel). 2021. PMID: 34944932 Free PMC article. Review.
-
Reliable anti-cancer drug sensitivity prediction and prioritization.Sci Rep. 2024 May 29;14(1):12303. doi: 10.1038/s41598-024-62956-6. Sci Rep. 2024. PMID: 38811639 Free PMC article.
-
Normal tissue transcriptional signatures for tumor-type-agnostic phenotype prediction.Sci Rep. 2024 Nov 8;14(1):27230. doi: 10.1038/s41598-024-76625-1. Sci Rep. 2024. PMID: 39516498 Free PMC article.
References
-
- Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 10.3322/caac.21492 (2018). - PubMed
-
- Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J. Clin. Oncol. 2013;31:1803–1805. - PubMed
-
- Doherty M, Metcalfe T, Guardino E, Peters E, Ramage L. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Ann. Oncol. 2016;27:1644–1646. - PubMed
-
- Heymach J, et al. Clinical Cancer Advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 2018;36:1020–1044. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
